company background image
1228

CANbridge Pharmaceuticals SEHK:1228 Stock Report

Last Price

HK$3.25

Market Cap

HK$1.4b

7D

-3.0%

1Y

n/a

Updated

17 Aug, 2022

Data

Company Financials +
1228 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

1228 Stock Overview

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.

CANbridge Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CANbridge Pharmaceuticals
Historical stock prices
Current Share PriceHK$3.25
52 Week HighHK$9.99
52 Week LowHK$3.25
Beta0
1 Month Change-13.33%
3 Month Change-22.06%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-63.48%

Recent News & Updates

Shareholder Returns

1228HK BiotechsHK Market
7D-3.0%1.4%1.5%
1Yn/a-51.7%-20.8%

Return vs Industry: Insufficient data to determine how 1228 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 1228 performed against the Hong Kong Market.

Price Volatility

Is 1228's price volatile compared to industry and market?
1228 volatility
1228 Average Weekly Movement5.6%
Biotechs Industry Average Movement7.8%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.8%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 1228 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1228's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012183James Qun Xuehttps://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid.

CANbridge Pharmaceuticals Inc. Fundamentals Summary

How do CANbridge Pharmaceuticals's earnings and revenue compare to its market cap?
1228 fundamental statistics
Market CapHK$1.38b
Earnings (TTM)-HK$1.24b
Revenue (TTM)HK$36.00m

38.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1228 income statement (TTM)
RevenueCN¥31.16m
Cost of RevenueCN¥12.39m
Gross ProfitCN¥18.78m
Other ExpensesCN¥1.10b
Earnings-CN¥1.08b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 24, 2022

Earnings per share (EPS)-2.54
Gross Margin60.25%
Net Profit Margin-3,456.26%
Debt/Equity Ratio4.5%

How did 1228 perform over the long term?

See historical performance and comparison